- Study: Community pharmacies are effective locations for rapid HIV testing
- At least 23,000 die from antibiotic-resistant infections each year, CDC finds
- Walgreens recognized for HIV Centers of Excellence program
- Helping independents compete in specialty pharmacy, Cardinal Health launches new suite of services at RBC 2013
- Cardinal Health invites independent pharmacy owners to ‘discover new horizons’ at RBC 2013
BOSTON — Almost twice as many drugs for neglected diseases have received regulatory approval around the world over the past few years compared with the beginning of the last decade, according to a new study.
Tufts University's Center for the Study of Drug Development found that between 2000 and 2008, an average of 2.6 new drugs were approved to treat neglected diseases each year, a number that increased to five per year between 2009 and 2012. Drugs for HIV/AIDS, malaria and tuberculosis accounted for 81% of the the products in development, while HIV/AIDS and malaria accounted for 60% of recent approvals. The study appeared in the Tufts CSDD July-August Impact Report.
"The trend in approvals is clearly going in the right direction, but annual research-and-development spending to treat neglected diseases has leveled off at $3 billion in total after rising rapidly from 2000 to 2007, which is a cause for concern," Tufts CSDD assistant professor and lead study author Joshua Cohen said. "While increased approvals may result in greater access to new medicines, policy makers need to ensure that safe, effective and easy-to-administer products are adopted by healthcare systems, that they are affordable and that they reach the people who need them."